Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer-Reference-Cited by-同舟云学术

Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer

Published:2017-11 Issue: Volume:86 Page:349-357
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Iijima Yuki,Hirotsu Yosuke,Amemiya Kenji,Ooka Yoshihiko,Mochizuki Hitoshi,Oyama Toshio,Nakagomi Takahiro,Uchida Yoshinori,Kobayashi Yoichi,Tsutsui Toshiharu,Kakizaki Yumiko,Goto Taichiro,Miyashita Yoshihiro,Omata Masao

Funder

Grant-in-Aid for Genome Research Project from Yamanashi Prefecture

Yasuda Medical Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas;McCarthy;Iowa Orthop J,2006

2. Enhancement of antitumor immunity by CTLA-4 blockade;Leach;Science,1996

3. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study;Wolchok;Lancet Oncol,2010

4. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

5. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brief Report: Tepotinib as a Treatment Option in MET Exon 14 Skipping-Positive Lung Cancers—Investigating Discordance Between ArcherMET and the Oncomine Dx Target Test;JTO Clinical and Research Reports;2024-06

2. High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer;Molecular & Cellular Proteomics;2024-05

3. Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients;Frontiers in Oncology;2023-12-19

4. Evolution of Biomarkers and Treatment Outcomes of Immunotherapy in Lung Cancer;Current Tissue Microenvironment Reports;2023-09-15

5. Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer;Clinical Cancer Research;2023-07-05